This project implements the Lox interpreter from Crafting Interpreters by Robert Nystrom using Kotlin. test-output.txt contains my unit testing results Chapter 4: Implemented a scanner that converts ...

Read about Recursive’s Flint AI coding model, its laptop-friendly design, coding benchmarks, open-source license, and Eureka Machine technology.

These past few days, the scope of AI's work has expanded from "writing new code" to "finding, fixing, and migrating holes in ...

Startup Recursive has released Flint, a free, laptop-sized coding model built largely by its own AI research system, as an early test of AI that improves itself.

Built on an evolutionary engine first released in 2018, STAR Fuzzer by Bright Security finds crashes, memory exhaustion and memory-safety bugs in security-critical code without a running application.

The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...